Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 1,228 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fusion Clear all
Recruiting No phase listed Observational

Complex Adult Deformity Surgery (CADS)

NCT04194138
View directory record Official record
Conditions
Adult Spinal Deformity, Scoliosis, Kyphosis, Sagittal Imbalance
Interventions
Index or spine revision surgery for complex adult spinal deformity
Procedure
Lead sponsor
International Spine Study Group Foundation
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2032
U.S. locations
17
States / cities
La Jolla, California • Sacramento, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 27, 2026, 1:53 PM EDT
Terminated Phase 2 Interventional Results available

Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment

NCT01521143
View directory record Official record
Conditions
Epithelial Ovarian Cancer
Interventions
Cvac, Placebo
Biological
Lead sponsor
Prima BioMed Ltd
Industry
Eligibility
18 Years and older · Female only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
6
States / cities
Los Angeles, California • Boynton Beach, Florida • Sarasota, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 27, 2026, 1:53 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00005633
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
OVA BiP peptide, gp209-2M antigen, recombinant 70-kD heat-shock protein, tyrosinase peptide
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 27, 2026, 1:53 PM EDT
Not listed Phase 2 Interventional

Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection

NCT04560569
View directory record Official record
Conditions
HIV/AIDS
Interventions
Albuvirtide, 3BNC117 Antibody
Drug
Lead sponsor
Frontier Biotechnologies Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Canoga Park, California • San Francisco, California • Hialeah, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 27, 2026, 1:53 PM EDT
Terminated Not applicable Interventional Results available

Pericapsular Exparel for Pain Relief in Bunionectomy and Related Procedures

NCT02499575
View directory record Official record
Conditions
Bunion, Hallux Rigidus
Interventions
0.5% ropivacaine, Exparel
Drug
Lead sponsor
OhioHealth
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Columbus, Ohio • Westerville, Ohio
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 27, 2026, 1:53 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Comparing Two Treatments That Both Target Smoking Cessation and Weight Loss at the Same Time.

NCT04130698
View directory record Official record
Conditions
Smoking Cessation, Weight Loss
Interventions
Distress Tolerance, transdermal nicotine patch, Active Health Control
Behavioral · Drug
Lead sponsor
Rhode Island College
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 27, 2026, 1:53 PM EDT
Completed No phase listed Observational

Sacroiliac (SI) Joint Transfixing and Fusion: Meaningful Long Term Outcomes With Nevro1

NCT06909292
View directory record Official record
Conditions
Sacroiliac Joint Dysfunction
Interventions
Sacroiliac Joint transfixing and fusion system (Nevro1)
Device
Lead sponsor
Nevro Corp
Industry
Eligibility
21 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
5
States / cities
Lodi, California • Southfield, Michigan • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 27, 2026, 1:53 PM EDT
Withdrawn No phase listed Observational

Enhanced Metal Reduction Techniques for Definitive CT Scanning to Assess Spinal Fusion With TM-Ardis

NCT02170558
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
TM- Ardis implant and Metal Reduction CT software
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boise, Idaho
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Oct 27, 2026, 1:53 PM EDT
Completed Not applicable Interventional

PRESTIGE® Cervical Disc Study

NCT00642876
View directory record Official record
Conditions
Degenerative Cervical Disc Disease
Interventions
Allograft Fusion and ATLANTIS™ Cervical Plate System, PRESTIGE® Cervical Disc
Device
Lead sponsor
Medtronic Spinal and Biologics
Industry
Eligibility
18 Years and older
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2013
U.S. locations
31
States / cities
Huntsville, Alabama • Montgomery, Alabama • Sacramento, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 27, 2026, 1:53 PM EDT
Completed Not applicable Interventional Results available

Treatment of Prepubertal Labial Adhesions

NCT02218463
View directory record Official record
Conditions
Prepubertal Labial Adhesions
Interventions
Estradiol cream 0.01%, Cetaphil
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
3 Months to 12 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 27, 2026, 1:53 PM EDT
Not listed Phase 1 Interventional

Vaccine Therapy and Interleukin-2 in Treating Young Patients With Relapsed or Refractory Ewing's Sarcoma or Neuroblastoma

NCT00101309
View directory record Official record
Conditions
Neuroblastoma, Sarcoma
Interventions
aldesleukin, autologous EBV-transformed B lymphoblastoid-tumor fusion cell vaccine, therapeutic autologous lymphocytes
Biological
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
1 Year to 30 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 27, 2026, 1:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

NCT02024087
View directory record Official record
Conditions
Advanced Adult Hepatocellular Carcinoma
Interventions
Dalantercept plus sorafenib
Drug
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
7
States / cities
Chicago, Illinois • Westwood, Kansas • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Oct 27, 2026, 1:53 PM EDT
Terminated Phase 3 Interventional Results available

SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC

NCT00440271
View directory record Official record
Conditions
HIV Infections
Interventions
tipranavir, ritonavir, Optimized Background Regimen (OBR)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
16
States / cities
Washington D.C., District of Columbia • Clearwater, Florida • Fort Lauderdale, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 27, 2026, 1:53 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Trial Assessing the Impact on Facial Skin Quality, Hydration, and Skin Barrier of Three (3) Hydrafacial Treatments in Adults of All Skin Types.

NCT05932732
View directory record Official record
Conditions
Cutis Laxa Facialis, Xeroderma
Interventions
HydraFacial Syndeo System, ReGen-GF, HydraFacial Elite MD System
Device · Drug
Lead sponsor
Austin Institute for Clinical Research
Network
Eligibility
30 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Houston, Texas • Pflugerville, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 27, 2026, 1:53 PM EDT
Active, not recruiting Phase 2 Interventional

Evaluating the Safety and Efficacy of Polyethylene Glycol (PEG) Mediated Fusion (PEG Fusion)

NCT04789044
View directory record Official record
Conditions
Peripheral Nerve Injuries
Interventions
NTX-001
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Baltimore, Maryland • Camden, New Jersey • Charlotte, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 27, 2026, 1:53 PM EDT
Completed Phase 2 Interventional

Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation

NCT01067287
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CT-011, Dendritic Cell Fusion Vaccine
Drug · Biological
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 27, 2026, 1:53 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

NCT05544552
View directory record Official record
Conditions
Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor, Urothelial Carcinoma, Solid Tumor, Adult, Bladder Cancer, Non-muscle-invasive Bladder Cancer, FGFR3 Gene Mutation, FGFR3 Gene Alteration, Advanced Solid Tumor, Advanced Urothelial Carcinoma, Urinary Tract Cancer, Urinary Tract Tumor, Urinary Tract Carcinoma
Interventions
TYRA-300
Drug
Lead sponsor
Tyra Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Boston, Massachusetts • Worchester, Massachusetts • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 27, 2026, 1:53 PM EDT
Recruiting Not applicable Interventional

Patient-centered, Optimal Integration of Survivorship and Palliative Care

NCT04900935
View directory record Official record
Conditions
Stage IV Non-small Cell Lung Cancer, Targeted Therapy, Nonsmall Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, ALK-positive Non-small Cell Lung Cancer, EGFR Positive Non-small Cell Lung Cancer, Palliative Care, Survivorship
Interventions
POISE
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 27, 2026, 1:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Gait and Postural Stability Assessment in Children With Idiopathic Scoliosis Undergoing Posterior Spine Instrumentation

NCT01109082
View directory record Official record
Conditions
Scoliosis
Interventions
posterior spine fusion
Procedure
Lead sponsor
Shriners Hospitals for Children
Other
Eligibility
1 Year to 20 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 19, 2013 · Synced Oct 27, 2026, 1:53 PM EDT
Enrolling by invitation No phase listed Observational

Advanced Materials Science in XLIF Study

NCT03649490
View directory record Official record
Conditions
Degenerative Disc Disease, Spondylolisthesis
Interventions
Not listed
Lead sponsor
NuVasive
Industry
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
15
States / cities
Hartford, Connecticut • Jacksonville, Florida • Tampa, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 27, 2026, 1:53 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL

NCT06022224
View directory record Official record
Conditions
COVID-19
Interventions
hAd5-S-Fusion+N-ETSD, Placebo (0.9% (w/v) saline)
Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
16 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 27, 2026, 1:53 PM EDT
Terminated Phase 2 Interventional Results available

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

NCT04383210
View directory record Official record
Conditions
Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer, Lung Cancer, Head and Neck Cancer, Breast Cancer, Kidney Cancer, Colorectal Cancer, Bladder Cancer, Ovarian Cancer, Sarcoma, Gallbladder Cancer, Bile Duct Cancer, Esophageal Cancer, Uterine Cancer, Cholangiocarcinoma, Prostate Cancer
Interventions
Seribantumab
Drug
Lead sponsor
Elevation Oncology
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fountain Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 27, 2026, 1:53 PM EDT
Terminated Phase 3 Interventional Results available

Comparison of Quadratus Lumborum Block Types

NCT04588389
View directory record Official record
Conditions
Pain, Opioid Use, Lumbar Disc Herniation
Interventions
Ropivacaine injection Location 1, Ropivacaine injection Location 2, Multimodal Pharmacological Management
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
40 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 27, 2026, 1:53 PM EDT
Withdrawn Not applicable Interventional

Evaluation of Cervical Fusion With DTRAX® Cervical Cage With DTRAX Bone Screw

NCT02694250
View directory record Official record
Conditions
Cervical Radiculopathy
Interventions
DTRAX® Cervical Cage with DTRAX Bone Screw
Device
Lead sponsor
Providence Medical Technology, Inc.
Industry
Eligibility
35 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
San Francisco, California • Daytona Beach, Florida • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 27, 2026, 1:53 PM EDT